Cancer Family
Head and Neck Neoplasm
CI-CAN-00000021Explore in graph →
Non-malignant1,571 active trials17 approved drugs142 evidence items
Loading cancer entity…
Cancer Family
CI-CAN-00000021Explore in graph →
Clinical trials
6,372 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06952868 | Boron Neutron Capture Therapy With B10 L-BPA for Unresectable Recurrent Head and Neck Cancers | recruiting | Phase 2 | 24 | China Medical University HospitalOTHER | 1 | Aug 28, 2026 | clinicaltrials |
| NCT04318717 | Pembrolizumab and Hypofractionated Radiation Therapy for the Treatment of Mucosal Melanoma | recruiting | Phase 2 | 20 | Washington University School of MedicineOTHER | 1 | Aug 27, 2026 | clinicaltrials |
| NCT07058805 | Compartmentalized Postoperative Radiotherapy in Head and Neck Cancer(COMPORT) | recruiting | Phase 2 | 50 | Olgun ElicinOTHER | 1 | Aug 27, 2026 | clinicaltrials |
| NCT06016920 | Safety and Efficacy of VB10.16 and Pembrolizumab in Patients With Head-Neck Squamous Cell Carcinoma | recruiting | Phase 1 / Phase 2 | 110 | Nykode Therapeutics ASAINDUSTRY | 7 | Aug 26, 2026 | clinicaltrials |
| NCT07392580 | Intralesional Chemotherapy (IC): Cisplatin + Epinephrine | recruiting | Phase 2 | 20 | University of MiamiOTHER | 1 | Aug 26, 2026 | clinicaltrials |
| NCT04901234 | Adaptive RadioTherapy for OroPharynx Cancer(ART-OPC) | recruiting | Phase 2 | 120 | Centre hospitalier de l'Université de Montréal (CHUM)OTHER | 2 | Aug 24, 2026 | clinicaltrials |
| NCT07781072 | Sintilimab Plus Hypofractionated Radiotherapy Followed by Chemoradiotherapy for Locally Advanced Head and Neck Squamous Cell Carcinoma | recruiting | Phase 2 | 27 | Second Affiliated Hospital, Zhejiang University, School of MedicineOTHER | 1 | Aug 24, 2026 | clinicaltrials |
| NCT07781358 | Becotatug Vedotin Combined With a PD-1 Inhibitor in the Treatment of Locally Advanced Recurrent Nasopharyngeal Carcinoma. | recruiting | Phase 2 | 25 | Hongmeng YuOTHER | 1 | Aug 24, 2026 | clinicaltrials |
| NCT06563362 | Personalized Volume-deescalated Elective Nodal Irradiation in Oropharyngeal Head and Neck Squamous Cell Carcinoma(DeEscO) | recruiting | Phase 2 | 120 | University of ZurichOTHER | 1 | Aug 21, 2026 | clinicaltrials |
| NCT06769698 | A Study to See if Giving Fianlimab and Cemiplimab Together is Better Than Cemiplimab Alone at Treating Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma | recruiting | Phase 2 | 120 | Regeneron PharmaceuticalsINDUSTRY | 5 | Aug 21, 2026 | clinicaltrials |
| NCT05269381 | Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for Treatment of Advanced Solid Tumors(PNeoVCA) | recruiting | Phase 1 / Phase 2 | 138 | Mayo ClinicOTHER | 1 | Aug 20, 2026 | clinicaltrials |
| NCT07777536 | Selective Coverage Versus Comprehensive Coverage Radiotherapy in Poorly Differentiated and Anaplastic Thyroid Cancer | recruiting | Phase 2 | 72 | Fudan UniversityOTHER | 1 | Aug 20, 2026 | clinicaltrials |
| NCT07115043 | A Study to Investigate Safety of AZD6750 in Adult Participants With Select Advanced or Metastatic Solid Tumors | recruiting | Phase 1 / Phase 2 | 120 | AstraZenecaINDUSTRY | 4 | Aug 19, 2026 | clinicaltrials |
| NCT06239220 | PD-L1 t-haNK, NAI IL-15sa and Cetuximab for Recurrent, Metastatic HNSCC | recruiting | Phase 2 | 25 | Dana-Farber Cancer InstituteOTHER | 1 | Aug 18, 2026 | clinicaltrials |
| NCT06995508 | Olanzapine for Managing Anorexia in Head and Neck Cancer Patients Undergoing Chemoradiation, MACRO Trial | recruiting | Phase 2 | 66 | Roswell Park Cancer InstituteOTHER | 1 | Aug 18, 2026 | clinicaltrials |
| NCT04333537 | Comparing Sentinel Lymph Node (SLN) Biopsy With Standard Neck Dissection for Patients With Early-Stage Oral Cavity Cancer | recruiting | Phase 2 / Phase 3 | 686 | NRG OncologyOTHER | 2 | Aug 17, 2026 | clinicaltrials |
| NCT04895709 | A Study of BMS-986340 as Monotherapy and as Combination Therapy in Participants With Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 1,109 | Bristol-Myers SquibbINDUSTRY | 8 | Aug 17, 2026 | clinicaltrials |
| NCT06532279 | Testing the Addition of the Drug BMX-001, a Radioprotector, or a Placebo to the Usual Chemoradiation Therapy for Patients With Head and Neck Cancer | recruiting | Phase 2 | 98 | NRG OncologyOTHER | 1 | Aug 17, 2026 | clinicaltrials |
| NCT07440290 | DETERMINE Trial Treatment Arm 07: Dabrafenib in Combination With Trametinib in Adult, Paediatric and Teenage/Young Adult Patients With BRAF V600 Mutation-Positive Cancers.(DETERMINE) | recruiting | Phase 2 / Phase 3 | 30 | Cancer Research UKOTHER | 1 | Aug 17, 2026 | clinicaltrials |
| NCT05985655 | Study to Assess GTAEXS617 in Participants With Advanced Solid Tumors(ELUCIDATE) | recruiting | Phase 1 / Phase 2 | 230 | Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc.INDUSTRY | 3 | Aug 13, 2026 | clinicaltrials |
| NCT07762976 | Dynamic Risk-adapted EBV-DNA and MRI-guided De-concurrent Chemotherapy in Nasopharyngeal Carcinoma | recruiting | Phase 2 | 148 | Fudan UniversityOTHER | 1 | Aug 13, 2026 | clinicaltrials |
| NCT05544136 | A Study of Decreasing Radiation Therapy and Chemotherapy in People With Head and Neck Cancer | recruiting | Phase 2 | 12 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Aug 12, 2026 | clinicaltrials |
| NCT05706129 | A Study to Assess Safety, Tolerability and Imaging Characteristics of [68Ga]Ga-DPI-4452 and to Assess Safety, Tolerability, and Efficacy of [177Lu]Lu-DPI-4452 in Participants With Unresectable Locally Advanced or Metastatic Solid Tumors | recruiting | Phase 1 / Phase 2 | 270 | Lumara Bio Oncologics GmbHINDUSTRY | 2 | Aug 11, 2026 | clinicaltrials |
| NCT05674396 | 3-5 FrAction Stereotactic Body Radiation Therapy for Palliation of Head and Neck Squamous Cell Carcinoma: the FAST Phase II Randomized Trial | recruiting | Phase 2 | 108 | M.D. Anderson Cancer CenterOTHER | 1 | Aug 10, 2026 | clinicaltrials |
| NCT07755449 | CLEAR (Cervical Lymphatic Exclusion in Adjuvant Radiation)(CLEAR) | recruiting | Phase 2 | 101 | Institut Català d'OncologiaOTHER | 1 | Aug 10, 2026 | clinicaltrials |
| NCT06515990 | A Study of DM005 in Patients With Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 208 | Doma Biopharmaceutical(Suzhou)Co., Ltd.INDUSTRY | 2 | Aug 7, 2026 | clinicaltrials |
| NCT06627270 | Antibiotic Treatment Effects on Intratumoral Bacteria Modulation in Surgical Patients With Oral Cancer | recruiting | Phase 2 | 30 | Case Comprehensive Cancer CenterOTHER | 1 | Aug 6, 2026 | clinicaltrials |
| NCT06891560 | A Study of Enfortumab Vedotin in People With Adenoid Cystic Carcinoma | recruiting | Phase 2 | 34 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Aug 6, 2026 | clinicaltrials |
| NCT04900623 | Risk-adapted Therapy in HPV+ Oropharyngeal Cancer Using Circulating Tumor (ct)HPV DNA Profile - The ReACT Study | recruiting | Phase 2 | 145 | Jonathan Schoenfeld, MD, MPHOTHER | 1 | Aug 5, 2026 | clinicaltrials |
| NCT06254911 | Pre-operative Atezolizumab in Patients With Resectable, Human Papillomavirus Related Oropharyngeal Carcinoma | recruiting | Phase 2 | 20 | Emory UniversityOTHER | 1 | Aug 5, 2026 | clinicaltrials |
| NCT06445114 | Using CircuLating Tumor DNA to Risk Adapt Post-Operative Therapy for HPV-associated Oropharyngeal Cancer | recruiting | Phase 2 | 50 | Zachary ZumstegOTHER | 1 | Aug 5, 2026 | clinicaltrials |
| NCT03099356 | Cyclophosphamide and Sirolimus for the Treatment of Metastatic, RAI-refractory, Differentiated Thyroid Cancer | recruiting | Phase 2 | 22 | University of Michigan Rogel Cancer CenterOTHER | 1 | Jul 31, 2026 | clinicaltrials |
| NCT07121595 | Personalized Neck Radiation Therapy Directed by Sentinel Lymph Node Biopsy for the Treatment of Oral Cavity Squamous Cell Carcinoma, PRECEDENT Trial | recruiting | Phase 2 | 50 | University of Michigan Rogel Cancer CenterOTHER | 1 | Jul 31, 2026 | clinicaltrials |
| NCT04657068 | A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors | recruiting | Phase 1 / Phase 2 | 542 | Artios Pharma LtdINDUSTRY | 4 | Jul 30, 2026 | clinicaltrials |
| NCT06448026 | Cemiplimab and Cetuximab Prior Salvage Surgery in Patients With Recurrent Oral Cavity and HPV-negative Oropharyngeal Squamous Cell Carcinoma | recruiting | Phase 2 | 17 | M.D. Anderson Cancer CenterOTHER | 1 | Jul 30, 2026 | clinicaltrials |
| NCT07172256 | CUE-101with Pembrolizumab for Locally Advanced HPV+HNSCCs | recruiting | Phase 2 | 30 | Yale UniversityOTHER | 1 | Jul 30, 2026 | clinicaltrials |
| NCT03526835 | A Study of Bispecific Antibody MCLA-158 in Patients With Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 560 | Merus B.V.INDUSTRY | 7 | Jul 29, 2026 | clinicaltrials |
| NCT04198766 | Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist) | recruiting | Phase 1 / Phase 2 | 340 | Inhibrx Biosciences, IncINDUSTRY | 4 | Jul 29, 2026 | clinicaltrials |
| NCT07522879 | A Study of Becotatug Vedotin (MRG003) Combined With Epirubicin as Neoadjuvant Therapy for EGFR-Positive, Unresectable Recurrent Sinonasal Adenoid Cystic Carcinoma(MRG003-SACC) | recruiting | Phase 2 | 40 | Eye & ENT Hospital of Fudan UniversityOTHER | 1 | Jul 28, 2026 | clinicaltrials |
| NCT06458036 | Selpercatinib Pre-RAI in Patients With RET Fusion Thyroid Cancer (RAISE)(RAISE) | recruiting | Phase 2 | 13 | Children's Hospital of PhiladelphiaOTHER | 1 | Jul 24, 2026 | clinicaltrials |
| NCT06702033 | The Minimalist Trial-2(MINT-2) | recruiting | Phase 2 | 142 | Washington University School of MedicineOTHER | 1 | Jul 24, 2026 | clinicaltrials |
| NCT06437522 | A Study of BL-B01D1+PD-1 Monoclonal Antibody in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma and Other Solid Tumors | recruiting | Phase 2 | 46 | Sichuan Baili Pharmaceutical Co., Ltd.INDUSTRY | 1 | Jul 23, 2026 | clinicaltrials |
| NCT06475300 | A Study of BL-B01D1+PD-1 Monoclonal Antibody in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer, Nasopharyngeal Carcinoma and Other Solid Tumors | recruiting | Phase 2 | 570 | Sichuan Baili Pharmaceutical Co., Ltd.INDUSTRY | 1 | Jul 23, 2026 | clinicaltrials |
| NCT07528183 | Maintenance Immunotherapy With Deferred Salvage Radiotherapy After Response to Chemoimmunotherapy in Recurrent Nasopharyngeal Carcinoma | recruiting | Phase 2 | 62 | Sun Yat-sen UniversityOTHER | 1 | Jul 23, 2026 | clinicaltrials |
| NCT05419089 | The Sinai Robotic Surgery Trial in HPV-related Oropharyngeal Squamous Cell Carcinoma (SIRS 2.0 Trial) | recruiting | Phase 2 | 83 | Icahn School of Medicine at Mount SinaiOTHER | 1 | Jul 22, 2026 | clinicaltrials |
| NCT05388773 | Transoral Surgical Resection Followed by De-escalated Adjuvant IMRT in Resectable p16+ Locally Advanced Oropharynx Cancer | recruiting | Phase 2 | 150 | Heath SkinnerOTHER | 1 | Jul 21, 2026 | clinicaltrials |
| NCT04852328 | Three Schedules of CUE-101 Administered Before Surgery or Definitive Chemoradiation Therapy in HLA-A*0201 Positive Patients With Locally Advanced, HPV16-Positive Oropharyngeal Squamous-Cell Carcinoma | recruiting | Phase 2 | 30 | Washington University School of MedicineOTHER | 1 | Jul 20, 2026 | clinicaltrials |
| NCT07059221 | A Trial of SHR-A2102 With Adebrelimab With or Without Other Anti-tumor Therapies in Recurrent/MetastaticHead and Neck Squamous Cell Carcinoma Cancer | recruiting | Phase 1 / Phase 2 | 210 | Suzhou Suncadia Biopharmaceuticals Co., Ltd.INDUSTRY | 1 | Jul 20, 2026 | clinicaltrials |
Data updated 22 days agoSource updated Aug 28, 2026source: clinicaltrials